AHSA1 (activator of HSP90 ATPase activity 1) functions as a co-chaperone that enhances HSP90 activity by stimulating its ATPase function 1. The protein competes with inhibitory co-chaperones for HSP90 binding, providing regulatory control over client protein chaperoning. AHSA1 is significantly overexpressed across multiple cancer types, including hepatocellular carcinoma, osteosarcoma, multiple myeloma, lung adenocarcinoma, head and neck squamous cell carcinoma, and pancreatic cancer 213456. In cancer contexts, AHSA1 promotes cellular proliferation, migration, invasion, and drug resistance through various mechanisms including Wnt/β-catenin pathway regulation and stabilization of survival proteins like IFI6 14. The protein serves as an independent prognostic factor associated with poor clinical outcomes in several malignancies 25. Therapeutically, AHSA1 represents a promising target, as its knockdown or pharmacological inhibition effectively suppresses tumor growth and overcomes drug resistance, particularly to proteasome inhibitors and tyrosine kinase inhibitors 34. These findings establish AHSA1 as both a diagnostic biomarker and therapeutic target in cancer management.